Screener
Fulgent Genetics, Inc. FLGT Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 7:08 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-199065
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Preferred stock, $0.0001 par value per share, 1,000 shares authorized, no shares issued or outstanding as of March 31, 2026, and December 31, 2025 | — | — |
| Additional paid-in capital | 540,141 | 574,520 |
| Accumulated other comprehensive income | 4,536 | 7,512 |
| Retained earnings | 505,128 | 529,954 |
| Total Fulgent stockholders’ equity | 1,049,809 | 1,111,989 |
| Noncontrolling interest | (5,655) | (5,274) |
| Total stockholders’ equity | 1,044,154 | 1,106,715 |
| Total liabilities and stockholders’ equity | $1,156,369 | $1,213,525 |
Item 1. Financial Statements.
FAQ
- What is Fulgent Genetics, Inc.'s total equity?
- Fulgent Genetics, Inc. (FLGT) reported total equity of $1.05B in Q1 2026.
- How has Fulgent Genetics, Inc.'s total equity changed year-over-year?
- Fulgent Genetics, Inc.'s total equity decreased by 6.9% year-over-year, from $1.13B to $1.05B.
- What is the long-term trend for Fulgent Genetics, Inc.'s total equity?
- Over 5 years (2020 to 2025), Fulgent Genetics, Inc.'s total equity has grown at a 14.3% compound annual growth rate (CAGR), from $569.39M to $1.11B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Fulgent Genetics, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude